Decipher® Genomic Prostate Cancer Test to Be Featured in Multiple Presentations and Events at Upcoming AUA Annual Meeting

SAN DIEGO, May 8, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that the company's Decipher® Prostate Cancer Classifier will be featured in multiple sessions during the American Urological Association (AUA) Annual Meeting taking place May 16-21 in Orlando, FL. Two data presentations will detail validation studies supporting the use of Decipher to predict risk of metastasis in men following prostate surgery. Decipher has also been included in independent CME and educational courses at AUA 2014. The Decipher test and a mobile app for urologists will also be the subject of an AUA Skills Challenge conducted at the GenomeDx exhibit booth.

AUA Skills Challenge
GenomeDx will be participating in the AUA's first annual Skills Challenge, hosting a hands-on challenge at the company's exhibit booth that will allow physicians to test drive the company's UroSketch 3D^TM mobile app and learn more about how genomic risk assessment tools might fit within their practice. The challenge will be held at the GenomeDx booth (# 1775) at the conference where physicians can also learn more about how the Decipher test and the company's soon to be launched second mobile application can transform patient management.

Decipher® Prostate Cancer Data Presentations
Abstract Title: "Independent validation of a genomic classifier in an at risk population of men conservatively managed after radical prostatectomy"
Date and Time: Tuesday, May 20, 1:00 p.m. to 3:00 p.m. EDT
Room W304E
Abstract #: MP74-06

Abstract Title: "Validation of a genomic classifier for predicting clinical progression following post-operative radiation therapy in high-risk prostate cancer"
Date and Time: Tuesday, May 20, 3:30 p.m. to 5:30 p.m. EDT
Room W307
Abstract #: MP79-01

Genomic Testing Educational Events
Several educational events will cover ground on the impact and use of genomic tests, including Decipher. Unless noted, these events are not sponsored by GenomeDx.

• Podium presentation PD34-07, titled "Natural History of Progression to PSA Recurrence and Metastasis Among at Risk Men Following Radical Prostatectomy," will highlight the clinical need for additional information, including molecular markers, to understand which men are candidates for aggressive treatment. The presentation will occur on Tuesday, May 20 during the Prostate Cancer: Epidemiology & Natural History II presentations, starting at 1:00 p.m. EDT in W303.
• A CME course titled "Management of Prostate Cancer: A Case Based Approach with Emphasis on Integrating New Molecular Diagnostics into Clinical Practice" will discuss how new molecular tests such as Decipher can be used to improve clinical decision making.  This course is taking place May 18 at the Orange County Convention Center.
• The presentation "Biomarkers in Prostate Cancer: Navigating the Diagnostic & Prognostic Utility" will review advances in prostate cancer biomarker development, their utility, and application to the clinical management of prostate cancer on May 20 in the S & T Hall at the Orange County Convention Center.
• A GenomeDx-sponsored lunch presentation featuring several noted urologists and covering the use of Decipher in clinical practice will be held during the educational course "Advanced Robotic Urology" taking place at the Florida Hospital Nicholson Center in Celebration, Florida on May 16.

GenomeDx will also present new data on validation of a 15 gene bladder cancer classifier for predicting post cystectomy cancer recurrence. The presentation (abstract # MP39-09) will occur on Sunday, May 18 during the Basic Research IV Bladder Cancer Poster Session taking place between 3:30 p.m. and 5:30 p.m. EDT in W 3014A. This poster has also been selected for display at the AUA/Urology Care Foundation's Research Honors Awards Program reception on May 16.

About Decipher
The Decipher® Prostate Cancer Classifier directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Decipher continues to demonstrate that it can accurately predict aggressive disease and help physicians make more informed treatment decisions for men with prostate cancer.

Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.

About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com.

Video - http://youtu.be/LQEgPoXO9vM

SOURCE GenomeDx Biosciences